Hyoscine

Indications
 Oral
Gastrointestinal tract spasm
Adult: As butylbromide: 20 mg 4 times daily.
Child: As butylbromide: 6-12 yr: 10 mg tid.
Oral
Genitourinary spasm
Adult: As butylbromide: 20 mg 4 times daily.
Child: As butylbromide: 6-12 yr: 10 mg tid.
Oral
Prophylaxis of motion sickness
Adult: As hydrobromide: 300 mcg 30 min before a journey, then 300 mcg every 6 hr if required. Max: 3 doses in 24 hr.
Child: As hydrobromide: 3-4 yr: 75 mcg 20 min before a journey, repeated if needed. Max dose: 150 mcg in 24 hr. 4-10 yr: 75-150 mcg, >10 yr: 150-300 mcg.
Max Dosage: 3 doses in 24 hrs.
Parenteral
Gastrointestinal tract spasm
Adult: As butylbromide: 20 mg IM/IV repeated after 30 min if needed. Max: 100 mg daily.
Max Dosage: 100 mg daily.
Parenteral
Genitourinary spasm
Adult: As butylbromide: 20 mg IM/IV repeated after 30 min if needed. Max: 100 mg daily.
Max Dosage: 100 mg daily.
Transdermal
Prophylaxis of motion sickness
Adult: As patch delivering 1 mg over 3 days: Apply 1 patch at least 4 hr before exposure to motion. To be applied behind the ear.
Subcutaneous
Prophylaxis of nausea and vomitting
Adult: As hydrobromide: 0.3-0.6 mg.
Child: As hydrobromide: 0.006 mg/kg.
Subcutaneous
Preoperative sedation
Adult: As hydrobromide: 0.6 mg 3-4 times daily.
Parenteral
Premedication before anaesthesia
Adult: As hydrobromide: 0.2-0.6 mg via SC or IM inj 30-60 minutes before induction of anesth.
Child: As hydrobromide: 15 mcg/kg via SC or IM inj, 30-60 minutes before induction of anesth.
Ophthalmic
Mydriasis and cycloplegia for refraction
Adult: As hydrobromide: Instil 1-2 drops of 0.25% soln to eye(s) 1 hr before procedure.
Child: As hydrobromide: Instil 1 drop of 0.25% soln to eye(s) bid for 2 days before procedure.
Ophthalmic
Iridocyclitis
Adult: As hydrobromide: Instil 1-2 drops of 0.25% solution to eye(s) up to 4 times daily.
Child: As hydrobromide: Instil 1 drop of 0.25% soln to eye(s) up to tid.
Contraindications
 Narrow-angle glaucoma, acute haemorrhage, paralytic ileus, tachycardia due to cardiac insufficiency, myasthenia gravis.
Warnings / Precautions
 Hepatic/renal disease, pyloric stenosis, urinary retention, prostatic hyperplasia, psychosis, seizure disorders, ulcerative colitis, coronary artery disease, tachyarrhythmias, heart failure, hypertension. Elderly, children, pregnancy, lactation.
Adverse Reactions
 Flushing, postural hypotension, tachycardia, fibrillation. Rarely psychotic reactions. Dizziness, drowsiness, fatigue, headache, memory loss. Dry skin, erythema, increased sensitivity to light, rash. Bloatedness, constipation, dry throat, dysphagia, nausea, vomiting, xerostomia. Dysuria, urinary retention. Tremor, weakness. Impaired accommodation, blurred vision, cycloplegia, dryness, narrow-angle glaucoma, increased intraocular pain, itching, photophobia, pupil dilation. Dry nose. Decreased diaphoresis, heat intolerance. Ophthalmic: Somnolence, dermatitis, oedema, exudate, follicular conjunctivitis, increased IOP, local irritation, photophobia, vascular and respiratory congestion.
Potentially Fatal: CNS depression, coma, circulatory and respiratory failure.
Overdose Reactions
 Symptoms: Dilated pupils, flushed skin, tachycardia, hypertension, ECG abnormalities, acute psychosis, CNS depression, circulatory collapse, hyperpyrexia, respiratory failure. Management: Artificial respiration with oxygen. Manage fever with ice or alcohol sponges. For severe life-threatening symptoms, give physostigmine 1-2 mg SC or IV slowly; repeat administration after 2 hr as necessary.
Drug Interactions
 Additive sedative effects with alcohol or other CNS depressants. Reduced effects with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine, tacrine).
Potentially Fatal: Effect potentiated by other anticholinergic drugs and TCAs.
See Below for More hyoscine Drug Interactions
Lab Interactions
 May interfere with the gastric secretion test.
Mechanism of Actions
 Hyoscine competitively blocks muscarinic receptors and has central and peripheral actions. It relaxes smooth muscle and reduces gastric and intestinal motility.
Onset: Oral, IM: 0.5-1 hr; IV: 10 min.
Duration: Oral, IM: 4-6 hr; IV: 2 hr.
Absorption: Tertiary salts: Readily absorbed. Quaternary salts: Poorly absorbed.
Distribution: Reversibly bound to plasma proteins.
Metabolism: Hepatic.
Excretion: Via urine (as metabolites); 4.8 hr (elimination half-life).
Storage Conditions
 Ophthalmic: Store at 8-27°C (46-80°F). Oral: Store at room temperature of 15-30°C (58-86°F). Parenteral: Store at room temperature of 15-30°C (58-86°F). Subcutaneous: Store at room temperature of 15-30°C (58-86°F). Transdermal: Store at 20-25°C (68-77°F).
Storage
 Ophthalmic: Store at 8-27°C (46-80°F). Oral: Store at room temperature of 15-30°C (58-86°F). Parenteral: Store at room temperature of 15-30°C (58-86°F). Subcutaneous: Store at room temperature of 15-30°C (58-86°F). Transdermal: Store at 20-25°C (68-77°F).
Available As
  • Hyoscine 0.0208 mg
  • Hyoscine Butyl Bromide 10 mg
  • Hyoscine Butyl Bromide 20 mg
  • Hyoscine Butyl Bromide 7.5 mg

    • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Hyoscine


    Hyoscine Containing Brands

    We are Developing Our database, More results coming soon.

    Hyoscine is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Hyoscine

    We are Developing Our database, More results coming soon.